1. Navarro J, Laguno M, Vilchez HH, Guardiola JM, Carrion JA, Force L, et al. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. J Antimicrob Chemother. 2017; 72: 2850-6. https://doi.org/10.1093/jac/dkx223.
2. Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population. Hepatology 2018; 67: 847-57. https://doi.org/10.1002/hep.29642.
3. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714–25. https://doi.org/10.1056/NEJMoa1503153.
4. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007; 147: 677–84. https://doi.org/10.7326/0003-4819-147-10-200711200-00003.
5. Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, et al. Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection. Hepatology. 2017; 66: 344-56. https://doi.org/10.1002/hep.29071.
6. EASL Recommendations on Treatment of Hepatitis C 2016 European Association for the Study of the Liver. J Hepatol. 2017; 66: 153-94. https://doi.org/10.1002/hep.29071.
7. EASL Recommendations on Treatment of Hepatitis C 2018 European Association for the Study of the Liver. J Hepatol. 2018; 2018; 69: 461-511. https://doi.org/10.1016/j.jhep.2018.03.026.
8. Sovaldi, INN-sofosbuvir – European Medicines Agency – Europa EU http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf
9. Daklinza, INN-daclatasvir – European Medicines Agency – Europa EU http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf
10. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61: 1127-35. https://doi.org/10.1002/hep.27726.
11. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016; 63: 1493–505. https://doi.org/10.1002/hep.28446.
12. Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferrière V, et al. Canadian Co-Infection Cohort Study. How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World? Clin Infect Dis. 2016; 62: 919-26. https://doi.org/10.1093/cid/civ1222.
13. Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Saf. 2016; 39: 589-611. https://doi.org/10.1007/s40264-016-0420-2.
14. Notari S, Tempestilli M, Fabbri G, Libertone R, Antinori A, et al. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1073: 183-90. https://doi.org/10.1016/j.jchromb.2017.12.018.
15. Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, etal. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017 18; 12: e0177352. https://doi.org/10.1371/journal.pone.0177352.
16. Faisal N, Bilodeau M, Aljudaibi B, Hirch G, Yoshida EM, Hussaini T, et al. Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study. Exp Clin Transplant. 2019; 17: 59-63. https://doi.org/10.6002/ect.2017.0201.
17. Virlogeux V, Choupeaux L, Pradat P, Maynard M, Bailly F, Scholtès C, et al. Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay. DigLiver Dis. 2016; 48: 1351-6. https://doi.org/10.1016/j.dld.2016.07.014.
18. Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, et al. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. Clin Pharmacokinet. 2017; 56: 1173-83. https://doi.org/10.1007/s40262-016-0504-2.
19. Parisi SG, Loregian A, Andreis S, Nannetti G, Cavinato S, Basso M, et al. Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin. Int J Infect Dis. 2016; 49: 151-3.
20. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ.Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001; 33: 562–9. https://doi.org/10.1086/321909.
21. Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013; 158: 658-66. https://doi.org/10.7326/0003-4819-158-9-201305070-00604.